Amgen Inc. (NASDAQ:AMGN) Shares Bought by Foresight Capital Management Advisors Inc.

Foresight Capital Management Advisors Inc. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 5.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 982 shares of the medical research company’s stock after purchasing an additional 50 shares during the period. Foresight Capital Management Advisors Inc.’s holdings in Amgen were worth $316,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Hershey Financial Advisers LLC bought a new stake in shares of Amgen in the 2nd quarter worth $30,000. nVerses Capital LLC acquired a new stake in shares of Amgen in the second quarter worth about $31,000. Bbjs Financial Advisors LLC bought a new position in Amgen during the second quarter valued at about $33,000. FSA Wealth Management LLC grew its stake in shares of Amgen by 182.0% in the 1st quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 91 shares during the period. Finally, Western Pacific Wealth Management LP grew its position in Amgen by 27.6% during the 1st quarter. Western Pacific Wealth Management LP now owns 162 shares of the medical research company’s stock worth $46,000 after acquiring an additional 35 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on AMGN shares. Bank of America increased their price target on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $305.00 price target (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Barclays upped their price target on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday. Wells Fargo & Company cut shares of Amgen from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. Finally, Cantor Fitzgerald started coverage on shares of Amgen in a research note on Friday, September 27th. They issued an “overweight” rating and a $405.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $326.30.

Amgen Trading Down 0.7 %

Shares of NASDAQ:AMGN traded down $2.21 during midday trading on Monday, reaching $317.45. The company had a trading volume of 1,261,193 shares, compared to its average volume of 2,488,611. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The firm has a market cap of $170.29 billion, a price-to-earnings ratio of 45.35, a price-to-earnings-growth ratio of 2.98 and a beta of 0.61. The company has a fifty day simple moving average of $327.28 and a two-hundred day simple moving average of $309.48.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. During the same period last year, the business earned $5.00 EPS. The business’s quarterly revenue was up 20.1% compared to the same quarter last year. Research analysts predict that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.84%. Amgen’s dividend payout ratio is 128.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.